NEW YORK, NY—Transcatheter edge-to-edge repair (TEER) with the Pascal system (Edwards Lifesciences) in patients with degenerative mitral regurgitation (MR) results in good early survival outcomes, ...
SAN FRANCISCO, CA—For patients with symptomatic degenerative mitral regurgitation (DMR) and a prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) with either of two approved devices ...
Edwards Lifesciences can say two things about its Pascal Precision Valve Repair System. The first is that the technology has FDA approval and the second is that in a study, the device showed its ...
BOSTON, Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary ...
SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...
NEW YORK CITY -- Real-world operators have been leaving patients with acceptable but still less-than-optimal results after transcatheter mitral edge-to-edge repair (M-TEER), with some suggesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results